A study done at IRB Barcelona and the Vrije Universiteit Brussel identifies camelid nanobodies able to block EGF, a protein that is abundant in tumour cells and that helps them to proliferate.
The digital newspaper Público and other media have echoed a study headed by the Universitat Autònoma de Barcelona (UAB) and involving researchers from the Chemistry and Molecular Pharmacology Programme at IRB Barcelona that offers a promising advance towards a treatment for Parkinson’s disease,.
Published in the journal PNAS, the study has revealed that a small molecule, called SynuClean-D, disrupts the formation of amyloid fibers of alpha-synuclein—the process that triggers the development of Parkinson’s disease—and reverses the neurodegeneration that ensues.
Jesús Garcia, Salvador Guardiola, Ernest Giralt and Xavier Salvatella...
For the scientific community, the protein POP (prolyl oligopeptidase) is an attractive therapeutic target for the treatment of cognitive and neurodegenerative disorders.
Scientists at IRB Barcelona have developed the first POP inhibitors that are irreversible, selective and brain-permeable.
Europa Press, El Economista, Technology Networks, News Medical, among other national and international media, have published an article about a study headed by IRB Barcelona that provides the first direct evidence of beta-amyloid dimers (two proteins joined together) in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers.
Link to Europa Press
A study headed by IRB Barcelona provides the first direct evidence of beta-amyloid dimers (two proteins joined together) in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers.
Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
The Meet Our Scientists series presents Ernest Giralt, doctor of chemical sciences, who is the head of the Peptides and Proteins laboratory at IRB Barcelona.
In the video "The power of medicinal chemistry", Giralt highlights his interest in deciphering the language used by proteins to interact with each other.
The Turkish media Aydinlik has published an article about the possibility of using poisons as medicine. The article includes a reference to the research on the use of bee venom as a strategy to selectively eliminate cancer cells, led by Ernest Giralt, leader of the Laboratory of Design, Synthesis and Structure of Peptides and Proteins of IRB Barcelona.
Link to Aydinlik
IRB Barcelona researcher Meritxell Teixidó has participated in the report "Menudes Teràpies" on the programme Quèquicom, broadcasted by Canal 33, There she talked about the advances made by the Design, Synthesis and Structure of Peptides and Proteins Lab, led by Ernest Giralt, regarding drugs with the capacity to overcome the blood-brain barrier and reach the brain.
Link to Menudes Teràpies
Link to additional clip
The technology supplement Innovadores of the newspaper El Mundo has echoed on the award of 220,000 euros to three biomedical innovation projects underway at IRB Barcelona. This funding has been given by the Agency for Management and University and Research Grants (AGAUR, acronym in Catalan) of the Catalan Government, with the support of ERDFs.
The labs headed by Angel R. Nebreda, Ernest Giralt and Roger Gomis secure funding for further development of three medical applications.
The three projects will receive 220,000 euros from the "Knowledge Industry" programme, which is run by the Catalan Government and cofunded by ERDFs.